Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Update

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 3,100,000 shares, a growth of 29.2% from the January 31st total of 2,400,000 shares. Based on an average trading volume of 327,700 shares, the days-to-cover ratio is presently 9.5 days. Currently, 15.1% of the company's stock are sold short.

Fractyl Health Stock Performance

Shares of GUTS stock traded down $0.16 during trading on Friday, reaching $1.41. The company had a trading volume of 258,802 shares, compared to its average volume of 307,000. The firm's 50 day simple moving average is $1.74 and its two-hundred day simple moving average is $2.25. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. Fractyl Health has a one year low of $1.37 and a one year high of $9.04. The company has a market capitalization of $67.82 million and a PE ratio of -0.12.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.08). Sell-side analysts forecast that Fractyl Health will post -1.61 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Jay David Caplan sold 22,346 shares of Fractyl Health stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the completion of the sale, the insider now directly owns 153,544 shares in the company, valued at $277,914.64. The trade was a 12.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Harith Rajagopalan sold 90,972 shares of Fractyl Health stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the sale, the chief executive officer now owns 491,329 shares of the company's stock, valued at approximately $894,218.78. This represents a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA raised its stake in shares of Fractyl Health by 4.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company's stock valued at $2,646,000 after acquiring an additional 49,289 shares in the last quarter. 683 Capital Management LLC increased its position in Fractyl Health by 4.0% in the 4th quarter. 683 Capital Management LLC now owns 650,000 shares of the company's stock worth $1,339,000 after buying an additional 25,000 shares during the period. Geode Capital Management LLC increased its position in Fractyl Health by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 513,079 shares of the company's stock worth $1,057,000 after buying an additional 11,603 shares during the period. Silverarc Capital Management LLC increased its position in Fractyl Health by 6.2% in the 4th quarter. Silverarc Capital Management LLC now owns 176,922 shares of the company's stock worth $364,000 after buying an additional 10,256 shares during the period. Finally, State Street Corp increased its position in Fractyl Health by 129.4% in the 3rd quarter. State Street Corp now owns 113,415 shares of the company's stock worth $287,000 after buying an additional 63,968 shares during the period.

Analysts Set New Price Targets

Separately, Morgan Stanley reduced their price target on Fractyl Health from $18.00 to $10.00 and set an "overweight" rating for the company in a report on Monday, February 3rd.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.